A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Garg, M, Hall, A, Jenner, M et al. (10 more authors) (2019) A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results. In: 61st ASH (American Society of Hematology) Annual Meeting & Exposition, 07-10 Dec 2019, Orlando, FL.

Metadata

Authors/Creators:
Dates:
  • Published: 13 November 2019
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 10 Jun 2021 13:01
Last Modified: 10 Jun 2021 13:01
Status: Published
Identification Number: https://doi.org/10.1182/blood-2019-126567
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics